6. Bibliografía

Adema G, de Boer AJ, van't Hullenaar R, et al.: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKIbeteb,HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 1993;143:1579–1585. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al.. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–3.

Baselga J: Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001;37 Suppl 1:S18–S24. Battyani Z, Grob J, Xerri L. et al.. PCR detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995;131:443-447. Berger SL Preparation and characterization of RNA: overview. Methods Enzymol 1987. 152:2159. Bernard F, Aerts I, Margueritte G, Astruc J. Micrometastases in pediatric oncology. Bull Cancer 2001; 88: 57780. Braun S, Muller M, Hepp F, et al.: Re: micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1998;90:1099–1101.

Braun S, Schlimok G, Heumos I, et al.: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcomeof stage I–III breast cancer patients. Cancer Res 2001;61:1890–1895.

Brossart P, Schmier J-W, Krüger S, et al.: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995;55:4056–4068. Bruggemann M; Raff T; Flohr T; Gokbuget N; Nakao M; Droese J; Luschen S; Pott C; Ritgen M; Scheuring U; Horst HA; Thiel E; Hoelzer D; Bartram CR; Kneba M. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006 Feb 1;107(3):1116-23. Epub 2005 Sep 29.

Campana, D. Determination of minimal residual disease in leukaemia patients. Br J Haematolo 2003; 121:823.

Campbell PJ, Morley AA. Modelling a minimal residual disease-based treatment strategy in childhood acute Iymphoblastic leukaemia. Br J Haematol 2003; 122:30-8. Carlson JA, Slominski A, Linette GP, Mihm MC Jr., Ross JS. Biomarkers in melanoma: predisposition,

limphoblastic leukaemia. Blood 2002; 100: 52-8.

Çodrington R, O'Connor He, Jalali GR, et al..

Analysis of ETV6/AML1 abnormalities in acute

lymphoblastic leukaemia: Incidence, alternative

spliced forms and minimal residual disease value.

Br J Haematol 2000; 111:1071.

Davids V, Kidson SH, Hanekom GS. Accurate

molecular detection of melanoma nodal metastases:

an assessment of multimarker assay specificity,

sensitivity, and detection rate. Mol Pathol

2003;56:43–51.

Davids V, Kidson SH, Hanekom GS. Melanoma

patient staging: histopathological versus molecular

evaluation of the sentinel node. Melanoma Res

2003;13:313–324.

Diéz Gilbert O. Técnicas de genética molecular II.

2006Estrov Z; Freedman MH.Detection of residual

disease in acute lymphoblastic leukemia of

childhood. Leuk Lymphoma 1999

Mar;33(1-2):47-52.

Diez-Martin J L et al.. Transplantes precursores

hematopoyéticos: enfermedad mínima residual y

quimerismo. Revista de la asociación española de

científicos 1999, 1.

Espinet B, Lloveras E, Solé F. Técnicas de

hibridación in situ (HIS). Fundamento y

aplicaciones en neoplasias hematológicas. Sangre

1999; 44: 261-267.

Estrov Z, Freedman MH. Detection of residual

disease in acute lymphoblastic leukemiaof

childhood. Leuk Lymphoma 1999; 33:47.

Ford AM; Bennett CA; Price CM; Bruin MC; Van

Wering ER; Greaves M. Fetal origins of the

TEL-AML1 fusion gene in identical twins with

leukemia. Proc Natl Acad Sci U S A 1998 Apr

14;95(8):4584-8.

Gameiro P; Moreira I; Yetgin S; Papaioannou M;

Potter MN; Prentice HG; Hoffbrand AV; Foroni L.

Polymerase chain reaction (PCR)- and reverse

transcription PCR-based minimal residual disease

detection in long-term follow-up of childhood acute

lymphoblastic leukaemia. Br J Haematol 2002

Dec;119(3):685-96.

Ghossein RA, Bhattacharya S: Molecular detection

and characteriation of circulating tumour cells and

micrometastases in solid tumours. Eur J Cancer

2000;36:1681–1694.

Ghossein RA, Rossi J. Polymerase chain reaction in

the detection of incrometastases and circulating

tumor cells, Cancer 1996, 76: 1.

Goulden N, Bader P, Van Der Velden V, Moppett J,

Schilham M, Masden HO, et al.. Minimal residual

disease prior to stem cell transplant for childRood

acute Iymphoblastic leuLaemia. Br J Haematol

2003; 122:24-9.

Gozzetti A, Le Beau MM: Fluorescence in situ

Takeuchi H, Umetani N, Hoon DS. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005;23(31):8057–8064. Lopez Almaraz, R., Raya Sanchez, J. M., Martinez Pineda, B. et al.. Estudio de la enfermedad mínima residual en el cáncer infantil. Oncología (Barc.). [online]. 2004, vol. 27, nº. 10. Lowdell MW; Craston R; Samuel D; Wood ME; O'Neill E; Saha V; Prentice HG. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002 Jun;117(4):821-7. Lee s, Kim DW, Cho B, et al., Risk factors for adults with Philadelphia-chromosomenpositive acute lymphoblastic leukaemia in remissiion treated with allogenic bone marrow transplantation: the potencial of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003;120:145. Lucas M. Diagnóstico molecular en genética médica. 1998.

Macfarlane DE,Dahle CE. lsolating RNA from whole blood: the dawn of RNA based diagnosis. Nature 1993 Mar 11;362(6416):186-8. Marskall GM, Haber M, Kwan E, Zhu L, Ferrara D, Chengyuan X, et al.. Importance of minimul residual disease testing during the second year of therapy for children with acute Iymphoblastic leukemia. J Clin Oncol 2003; 21:704-9.

McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459–465Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quinto L, et al.. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002;20:4032–4039. Mellado B, Colomer D, Castel T, et al.. Detection of circulating neoplastic cells by reverse-transcriptase polymerase Caín reaction in malignant melanoma: association with clinicla stage and prognosis. J. Clin Oncol 1996; 14:2091-2097. Moppett J, BurLe GA, Steward CG, Oakhill A, Goulden NJ. The clinical relevance of detection of minimal residual disease in childhood acute Iymphoblastic leukaemia. J Clin Pathol 2003; 56:249-53.

Murata-Collins J L, Zhang F, Tcheurekdjian L, Slovak M L. Interphase Special FISH: Tailoring a diagnostic and minimal residual disease (MRD) assay for oncology.Genetics in Medicine. 2(1):94, January/February 2000.

Nathan CA, Franklin S, Abreo FW, et al.: analysis of surgical margins with the molecular marker EIF4E: a prognostic factor in patients with head

tumor cells in melanoma: a review of the literature

and description of a novel technique. Proc (Bayl

Univ Med Cent) 2008;21(2):127–132.

Sievers EL, Radich JP. Detection of minimal

residual disease in acute leukemia. Curr Opin

Hematol 2000; 7:212-6.

Shono K, Taliri T, Fujii Y, Suita S. Clinical

implications of minimul disease in bone marrow and

peripheral blood in neuroblastoma. J Pediatr Surg

2000; 35:1415-20.

Smith B, Selby P, Southgate J, et al.: Detection of

melanoma cells in peripheral blood by means of

reverse transcriptase and polymerase Caín reaction.

Lancet 1991; 338(8777):1227-1229.

Spinet B, Lloveras E, Solé F. Técnicas de

hibridación in situ (HIS) Fundamento y aplicaciones

en neoplasisas hematológicas. Sangre 1999; 44:

261-267.

Tomás J.F., Román A., Subirá D., Vizcarra E.,

Llamas P., Fernández de Velasco J. Enfermedad

mínima residual. Significado de la remisión en

enfermedades oncohematológicas. Haematologica

(ed. Esp.), volumen 89, extraordin 1, octubre 2004.

Uzunel M, Jaksch M, Mattsson J, Ringden O.

Minimal residual detection aker allogenic stem cell

transplantation is correlated to relapse in patients

with acute Iymphoblastic leukaemia. Br J Haematol

2003; 122:788-94.

Uzunel M; Mattsson J; Jaksch M; Remberger M;

Ringden O. The significance of graft-versus-host

disease and pretransplantation minimal residual

disease status to outcome after allogeneic stem cell

Carlson JA, Slominski A, Linette GP, Mihm MC Jr., Ross JS. Biomarkers in melanoma: staging, prognosis and detection of early metastases. Expert Rev Mol Diagn 2003;3:303–330. Carrel S, Dore JF, Ruiter D, et al.: The EORTC melanoma group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer 1991;48:836–847. Catasús Uy Matias Gulp X. Técnicas moleculares para a obtención del ADN y reacción en cadena de la polimerarsa. Rev Exp Patel 1997: 30: 163 8. Cave H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998 Aug 27;339(9):591-8.

Cimino G; Elia L; Rapanotti MC; Sprovieri T; Mancini M; Cuneo A; Mecucci C; Fioritoni G; Carotenuto M; Morra E; Liso V; Annino L; Saglio G; De Rossi G; Foa R; Mandelli F. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 2000 Jan 1;95(1):96-101.

Chomel JC; Brizard F; Veinstein A; Rivet J; Sadoun A; Kitzis A; Guilhot F; Brizard A. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000 Jan 15;95(2):404-8. Corradini P, Voena C, Astolfi M, Dell’Oro S, Pilotti S, Arrigoni G, Bregni M, Pileri A, Gianni A M. Los genes maspina y mamaglobulina son marcadores específicos para la detección con PCR-TI de enfermedad mínima residual en pacientes con cáncer de mama. Annañs of Oncology 2002; 11: 195-200.

Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukaemia. Blood 2000 Oct 15;96(8):2691-6. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razouk Bl, Ribeiro RC et al.. Prognostic importance of measuring early clearance of leuRemic cells by flow cytometry in childhood acute

hybridization: uses and limitations. Semin Hematol 2000;37:320–333.

Harrison. Principios de medicina interna. 1994; 13ª ed. Vol II2153-2157.

Hermanek P: Disseminated tumor cells versus micrometastasis: definitions and problems. Anticancer Res 1999;19:2771–2774. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, Morton DL. Molecular markers in blood as surrogate prognostic indicators ofmelanoma recurrence. Cancer Res 2000;60(8):2253–2257. Jeannine Lacroix, Md,* And Magnus Von Knebel Doeberitz, Md. Technical Aspects Of Minimal Residual Disease Detection In Carcinoma Patients. Seminars In Surgical Oncology 2001; 20:252–264 Jiménez A, Román J, Agirre X, Barrios M, Navarro G, San José Enériz E, Cordeu L, Gárate L, Castillejo J A, Prosper F, Torres A, Heiniger A I. PCR en tiempo real, una nueva herramienta para la toma de decisiones clínicas. Hematológica edición espaola 2006; 91(Supl 1) 27-34. Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol 1996;23:205–210.

Kasprzy A, Secker-Walker LM. Increased sensitivity of minimalesidual disease detection by interphase FISH in acute lymphoblastic leukaemia with hyperdyploidy. Leukemia 1997; 11:429:435. Kawakami Y, Eliyahu S, Delgado CH, et al.: Cloning the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumour. Proc Natl Acad Sci U S A 1994;91:3515–3519.

Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Muller I; Niethammer D; Bader P. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005 Mar;128(6):774-8. Knechtli CJ; Goulden NJ; Hancock JP; Harris EL; Garland RJ; Jones CG; Grandage VL; Rowbottom AW; Green AF; Clarke E; Lankester AW; Potter MN; Cornish JM; Pamphilon DH; Steward CG; Oakhill A. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998 Aug;102(3):860-71.

Koch M, Weitz J, Kienle P, et al.: Comparative analysis of tumor cell dissemination in mesenteric, central, and peripheral venous blood in patients with colorectal cancer. Arch Surg 2001;136:85–89. Koyanagi K, O’Day SJ, Gonzalez R, Lewis K, Robinson WA, AmatrudaTT, Wang HJ, Elashoff RM,

and neck cancer. J Clin Oncol 1999;17:2909-2914.

Nicole Max Phd, Ulrich Keilholz Md. Minimal

Residual Disease in MelanomaSeminars in Surgical

Oncology 2001; 20:319–328.

Orfao A. La citometría de flujo en el laboratorio

clínico.1995.

Palmieri G, Ascierto P. A., Perrone F.,.Satriano S.

M. R ,. Ottaiano A, Daponte A., Napolitano M.,

Caraco C., Mozzillo N., Melucci M. T., Cossu A.,

Tanda F., Gallo C.,Satriano R. A., and Castello G.

Prognostic Value of Circulating Melanoma Cells

Detected by Reverse Transcriptase–Polymerase

Chain Reaction. J Clin Oncol 21:767-773. 2003 by

American Society of Clinical Oncology.

Pantel K, Otte M. Disseminated tumor cells:

diagnosis, prognostic relevance, and phenotyping.

Recent Results Cancer Res 2001; 158: 14-24.

Pantel K, von Knebel DM: Detection and clinical

relevance of micrometastic cancer cells. Curr

Opinion Oncology 200; 12:95-101.

Peck K, Sher YP, Shih JY, et al.: Detection and

quantitation of circulating cancer cells in the

peripheral blood of lung cancer patients.Cancer Res

1998;58:2761–2765.

de Plaen E, Arden K, Traversari C, et al.: Structure,

chromosomal localization and expression of twelve

genes of the MAGE family.Immunogenetics

1994;40:360–369.

Quaglino P, Savoia P, Fierro MT, Osella-Abate S,

Bermengo MG. Clinical significance of sequential

tyrosinase expresión in the pheripheal blood of

disease-free melanoma patients: a review of

literature data. Melanoma Res 2004; 14:sS17-S19.

Raff T, Gokbuget N, Luschen S, et al.. Molecular

relapse in adult standard-risk ALL patients detectec

by prospective MDR monitoring during and after

maintence treatment:data from the GMALL 06/99

and 07/03 trials. Blood 2007;109-910.

Ramirez-Rodríguez J M, Aguilella-Diago V. recidiva

local en el cáncer de colón y recto. Cir Esp 2005;78

(6): 344-350.

Ravindranath Y. Recent advances in pediatric acute

Iymphoblastic and myeloid leucemia. Curr Opin

Oncol 2003; 15:23-35.

Rimoldi D, Lemoine R, Kurt AM, Salvi S, Berset M,

Matter M, et al.. Detection of micrometastases in

sentinel lymph nodes from melanoma patients:

direct comparison of multimarker molecular and

immunopathological methods. Melanoma Res

2003;13:511–520.

Roberts WM; Estrov Z; Ouspenskaia MV; Johnston

DA; McClain KL; Zipf TF. Measurement of residual

leukemia during remission in childhood acute

lymphoblastic leukemia. N Engl J Med 1997 Jan

30;336(5):317-23.

Shawn Steen, MD, John Nemunaitis, MD, Tammy

Fisher, RN, and Joseph Kuhn, MD. Circulating

transplantation in patients with acute lymphoblastic leukemia. Blood 2001 Sep 15;98(6):1982-4. Van der Toorm PP, Veltman JA, Bot FJ, et al.. Mapping of resection margins of oral cancer for p53 overexpression and chromosome instability to detect residual (pre)malignant cells. J Pathol 2001 ; 193 :66-72.

Van Dongen JJ, Szczepanski T, de Bruijn MA, et al.. Detection of minimal residual disease in acute leukaemia patients. Cytokines Mol Ther 1996; 2:121.

Visús C, Andres R, Mayordomo J I, Martinez-Lorenzo M J, Murillo L, Sáez_Gutiérrez B, Diestre C, Marcos I, Astier P, Rodino J, Parapeto-Marquez de Prado F J, Larrad L, Tres A. Prognostic role of circulating melanoma cells detected by reverse transcriptasenpolimerase Chain reaction for tyrosinase mRNA in patines with melanoma. Melanoma Research 2007, 17:83-89. Vora A; Frost L; Goodeve A; Wilson G; Ireland RM; Lilleyman J; Eden T; Peake I; Richards S. Late relapsing childhood lymphoblastic leukemia. Blood 1998 Oct 1;92(7):2334-7. Zhou J; Goldwasser MA; Li A; Dahlberg SE; Neuberg D; Wang H; Dalton V; McBride KD; Sallan SE; Silverman LB; Gribben JG. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007 Sep 1;110(5):1607-11. Epub 2007 May 7.